🔗 Share this article

While the US undertakes historic revisions to its immunization guidelines, one figure has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by questioning COVID-19 vaccinations during the global health crisis and has focused upon alleged deaths following COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Vaccine Program

Health officials had intended to unveil major revisions to the childhood immunization program earlier this month, aligning the US with Denmark’s immunization schedule, it is understood – a significant shift that would put the US out of alignment with much of the global community with insufficient data for public health gain. The announcement has been delayed until the coming year.

Rather than the top vaccines chief, Høeg is scheduled to address the audience at the meeting. She was just designated interim head of the FDA’s CDER, the fifth appointee to lead the center this year.

A Shift at the Regulatory Body

This interim role might represent a closer partnership between the drug and vaccine branches as Høeg and Prasad solidify control at the FDA – and it suggests a renewed priority upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for discontinuing specific pediatric vaccine recommendations in the US so as to align more similar to Denmark's approach, a society with nationalized medicine and a number of inhabitants approximately the size of Wisconsin’s.

In her initial comments, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Expertise

Høeg has no apparent experience in medication creation, regulation or administrative roles, which has been typical for previous directors of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, said Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a major agency. She has no expertise in pharmaceutical oversight.”

Previous heads of CBER would “understand legal statutes and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that prior appointees who led CBER have had.”

This division has an enormous portfolio at the agency, she emphasized.

“Many people just focuses on the innovative therapies, but the generic program approves numerous generic medications. There is also a biologic copycat branch, over-the-counter program and other areas, and all of those need to be looked after,” Woodcock said. “The area you overlook, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial management component to the role, which manages more than 5,000 employees. “It is a enormous management job, if you perform it correctly,” she concluded.

Response and Disputed Programs

In response to inquiries about Høeg’s fitness for the role and whether this selection indicates more teamwork among FDA leaders on vaccines, a representative stated that the “concerns are based on inaccurate presumptions”.

“Her experience matches the duties of her job,” the official stated, noting the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious one-day therapy clearance system that apparently worried her former heads. “How are these drugs being chosen for this voucher program? Who takes the choices?” Dr. Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

In general, he remarked, “the FDA seems to be moving towards laxer regulations of pharmaceuticals, except for shots.”

Public History on Immunizations

With immunizations, Dr. Høeg has a clearer, if problematic, history, some experts have noted. She published a analysis using unverified public submissions to assess the incidence of myocarditis following COVID-19 vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Part of her “wish list” for the new government included changing guidelines for new vaccines and ending “non-essential” immunizations, she stated post-election on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of preventing teenage boys from obtaining Covid vaccinations.

“She’s an all-around ideologue who starts off with her preconceived notions and reverse-engineers to fit the science in a very disingenuous, dishonest way,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with fellow dissenters, {like|